Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jul;44(7):1729-1734.
doi: 10.1007/s10096-025-05128-2. Epub 2025 Apr 9.

Treatment of pre-extensively drug-resistant tuberculosis in a 4-month-old infant using a regimen of bedaquiline, delamanid, and contezolid

Wenrui Ding #  1 , Lingyun Shen #  2 , Ruonan Li  1 , Xiaotao Yang  1 , Yanchun Wang  3 , Yonghan Luo  4   5
Affiliations
Case Reports

Treatment of pre-extensively drug-resistant tuberculosis in a 4-month-old infant using a regimen of bedaquiline, delamanid, and contezolid

Wenrui Ding et al. Eur J Clin Microbiol Infect Dis. 2025 Jul.

Abstract
in English, German

Drug-resistant tuberculosis (TB) is a significant global challenge, especially in children, where diagnosis and treatment are difficult. This report describes a 4-month-old male infant with pre-extensively drug-resistant tuberculosis (pre-XDR-TB) successfully treated with bedaquiline, delamanid, and contezolid. The patient, born prematurely, developed severe pulmonary TB after exposure to drug-resistant TB from the mother. After discontinuing the initial regimen due to adverse effects, the adjusted regimen resulted in negative TB culture conversion, significant pulmonary improvement, and no notable adverse effects.

Not applicable.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This case report was approved by the Ethics Review Committee of the Children’s Hospital of Kunming Medical University. The guardians of the infant patient were contacted, and informed consent was obtained for the publication of this case report. All methods were carried out in accordance with relevant guidelines and regulations, including the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. Jenkins HE, Tolman AW, Yuen CM, Parr JB, Keshavjee S, Pérez-Vélez CM, Pagano M, Becerra MC, Cohen T (2014) Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet 383(9928):1572–1579 - PubMed - PMC
    1. Jenkins HE, Yuen CM (2018) The burden of multidrug-resistant tuberculosis in children. Int J Tuberc Lung Dis 22(5):3–6 - PubMed
    1. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J et al (2020) Treatment of highly Drug-Resistant pulmonary tuberculosis. N Engl J Med 382(10):893–902 - PubMed - PMC
    1. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, Samoilova A, Skornykova S, Tudor E, Variava E et al (2022) Bedaquiline-Pretomanid-Linezolid regimens for Drug-Resistant tuberculosis. N Engl J Med 387(9):810–823 - PubMed - PMC
    1. Xiong YJ, Xiao Y, Xie L, Gao L, Han Y, Huang PF, Liu S, Liang YX, Wang H (2024) Contezolid for the treatment of Drug-Resistant tuberculosis in China: A clinical case series. Infect Drug Resist 17:3491–3499 - PubMed - PMC

Publication types

MeSH terms

LinkOut - more resources